Collectively, targeting the pathways of oxidative stress and inflammatory responses in patients with concomitant AS and DM may present novel therapeutic options for slowing AS progression and alleviating HF symptoms by enhancing titin phosphorylation and mitigating cardiomyocyte Fpassive. The gene discussed is TTN; the disease is aortic valve stenosis.